NCT06902428View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

June 5, 2026

Study Completion Date

July 3, 2026

Conditions

Behcet's Disease

Interventions

DRUG

HSK44459

HSK44459, bid p.o.

DRUG

Placebo

Placebo, bid p.o.

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY